Vaccine (mRNA vaccine) · Immune activation, directed at PRAME · developed by Immatics US
mRNA-4203 (anzu-cel) is a lipid nanoparticle-encapsulated mRNA cancer vaccine encoding the tumor-associated antigen PRAME. After uptake and translation by antigen presenting cells, the PRAME epitope is presented on MHC molecules to induce cytotoxic and memory T-cell responses against PRAME-expressing cancer cells. It is studied in cutaneous melanoma and synovial sarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06946225 | Phase 1 | Cutaneous Melanoma | Recruiting | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cutaneous MelanomaSynovial Sarcoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →